Impact of the 2018 ASCO/CAP HER2 guidelines update for HER2 testing by FISH in breast cancer

Recently, the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) updated the guidelines on HER2 testing for invasive breast cancer. Little is known about the impact of the guidelines update. We aimed to study the impact of the 2018 ASCO/CAP HER2 testing guidelines upda...

Full description

Saved in:
Bibliographic Details
Published in:Pathology, research and practice research and practice, 2019-02, Vol.215 (2), p.251-255
Main Authors: Xu, Bin, Shen, Jianguo, Guo, Wenhao, Zhao, Wenhe, Zhuang, Yiyu, Wang, Linbo
Format: Article
Language:English
Subjects:
Biomarkers, Tumor - analysis
Breast cancer
Breast Neoplasms - classification
Breast Neoplasms - mortality
Female
Fluorescence in situ hybridization (FISH)
Guidelines as Topic
HER2
Humans
In Situ Hybridization, Fluorescence - methods
Kaplan-Meier Estimate
Receptor, ErbB-2 - analysis
The 2018 ASCO/CAP guidelines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recently, the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) updated the guidelines on HER2 testing for invasive breast cancer. Little is known about the impact of the guidelines update. We aimed to study the impact of the 2018 ASCO/CAP HER2 testing guidelines update. We compared the HER2 FISH results interpreted by 2013 and 2018 ASCO/CAP guidelines in 331 cases of invasive breast cancers. We also analyzed the pathological features and clinical outcomes of these cases. In comparing to the 2013 ASCO/CAP guidelines, the HER2 negative rate was increased significantly from 62.5% to 75.8%(P 
ISSN:0344-0338
1618-0631
DOI:10.1016/j.prp.2018.10.035